HF
CLDI icon

HRT Financial’s Calidi Biotherapeutics CLDI Stock Holding History

HRT Financial’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Buy
+10,133
New +$7.61K ﹤0.01% 3673
2025
Q3 		– Sell
-3,634
Closed -$10K – 2937
2025
Q2 		$10K Buy
+3,634
New +$17.6K ﹤0.01% 2453
2025
Q1 		– Sell
-1,313
Closed -$18K – 2609
2024
Q4 		$18K Buy
+1,313
New +$24.6K ﹤0.01% 2218
2024
Q3 		– Sell
-845
Closed -$20K – 2511
2024
Q2 		$20K Buy
845
+728
+622% +$23.3K ﹤0.01% 1934
2024
Q1 		$7K Sell
117
-21
-15% -$2.15K ﹤0.01% 2090
2023
Q4 		$25K Buy
138
+52
+60% +$14K ﹤0.01% 2018
2023
Q3 		$34K Sell
86
-4
-4% -$4.05K ﹤0.01% 2028
2023
Q2 		$113K Hold
90
– – ﹤0.01% 1949
2023
Q1 		$111K Hold
90
– – ﹤0.01% 2042
2022
Q4 		$110K Sell
90
-1
-1% -$1.2K ﹤0.01% 2048
2022
Q3 		$107K Buy
+91
New +$109K ﹤0.01% 2380

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HRT Financial's CLDI Position: Q1 2026 in Review

HRT Financial opened a new position in Calidi Biotherapeutics (CLDI) in Q1 2026: 10,133 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #3673 among its holdings. This is a return to the name: HRT Financial previously reported a position in CLDI as recently as Q2 2025.

HRT Financial first reported a position in CLDI in Q3 2022 and has held it in 11 quarters since. The position peaked at $113K in Q2 2023. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • HRT Financial held 10,133 shares of Calidi Biotherapeutics worth $2K as of Q1 2026.
  • Calidi Biotherapeutics was a new HRT Financial position in Q1 2026.
  • Calidi Biotherapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3673 holding.
  • HRT Financial first reported a position in Calidi Biotherapeutics in Q3 2022 and has held it in 11 quarters since.
  • HRT Financial's Calidi Biotherapeutics position peaked at $113K in Q2 2023.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.